TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07312188: A Phase II Study of F182112 Combined With Different Administration Regimens in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor: Shandong New Time Pharmaceutical Co., LTD · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07312188 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07312188 Rescue Dossier →